Differences in Clinical Aspects Between Subacute Thyroiditis Associated with COVID-19 Vaccines and Classical Subacute Thyroiditis
Horm Metab Res 2022; 54: 380-388 DOI: 10.1055/a-1840-4374Subacute thyroiditis (SAT) developed after SARS-CoV-2 vaccines has been less
studied. We aimed to compare classical SAT and SAT developed after SARS-CoV-2
vaccines in the context of clinical aspects. Adults with SAT detected in 90 days
of COVID-19 vaccination (CoronaVac or Pfizer/BioNTech) were grouped as
Vac-SAT. Those with a history of SARS-CoV-2 or upper respiratory tract infection
in 6 months before the vaccination, or vaccination with another antiviral
vaccine after COVID-19 vaccination were excluded. Those with SAT detected before
COVID-19 pandemic were grouped as Classical-SAT. Of total (n=85),
female/male (54/31) ratio and age [43 (23–65)] were
similar in Vac-SAT (n=23) and Classical-SAT (n=62). Duration
between vaccine and SAT was 45 (7–90) days, and similar in CoronaVac-SAT
(n=5) and BioNTech-SAT (n=18). SAT-duration was 28
(10–150) days, and higher in Vac-SAT than in Classical-SAT
(p=0.023). SAT was developed after the 1st dose vaccine in minority in
CoronaVac-SAT (n=2) and BioNTech-SAT (n=3) (p=0.263).
Previous LT4 use, and TSH elevation after resolution were more frequent in
Vac-SAT than in Classical-SAT (p=0.027 and p=0.041). We included
a considerable number of patients with SAT occurred after COVID-19 vaccines. We
cannot ...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Topalo ğlu, Ömercan Tekin, Sakin Topalo ğlu, Seda Nur Bayraktaroglu, Taner Tags: Original Article: Endocrine Care Source Type: research
More News: Covid Vaccine | COVID-19 | Endocrinology | Hormones | Pandemics | Pfizer | Respiratory Medicine | SARS | Thyroiditis | Vaccines